Alerts

Ritalin and Artige immediate-release tablets are now also in shortage, and a shortage of Ritalin LA capsules is anticipated.

Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.

The supply of Ozempic (semaglutide) will continue to be limited until 31 December 2025

Pharmacists can use a Serious Scarcity Substitution Instrument (SSSI) to dispense Protaphane Penfill human insulin in the place of a Protaphane InnoLet cartridge.

Pharmacists may dispense alternative brands or strengths without a new prescription.

Pharmacists can now substitute one Orencia 125 mg product for the other

The TGA is warning consumers against taking EVE branded products that contain allylisopropylacetylurea (apronal) as they pose a significant health risk and are prohibited from sale, supply or use in Australia.

The TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.

The shortage of Metalyse (tenecteplase) is now resolved.

Alternative product approved to address expected shortage

Safety advisory - alternative product filling shortage may cause airway irritation if administered via inhalation